Revolution Medicines announced unprecedented Phase 3 results in pancreatic cancer
Arctic Aurora LifeScience holding, Revolution Medicines announced outstanding overall survival benefit in metastatic pancreatic cancer, one of the most lethal tumors.
Transactions & Deals
April 2026
Dolphin Drilling AS — Private placement
NOK 590M
March 2026
Jadestone Energy — Senior secured bond issue
$200M
March 2026
Wästbygg Gruppen AB — Bridge Loan
SEK 140M
March 2026
Wästbygg Gruppen AB — Rights Issue
SEK 191M
March 2026
General Oceans — IPO
NOK 1.2B
March 2026
SED Energy Holdings Plc. — Block trade
NOK 220M
March 2026
Keenfinity Group — Senior secured bond issue
€325M
March 2026
LogCap Invest AS — Senior secured bond issue
NOK 3.9B
March 2026
Rasmussengruppen — Secondary sale in B2 Impact ASA
NOK 400M
March 2026
Rec Silicon — Rights Issue
NOK 973M
March 2026
Norvestor — Recommended voluntary cash tender offer
Undisclosed
March 2026
Navios South American Logistics, Inc. — Senior secured bond tap issue
$30M
March 2026
Studentbostäder i Norden — Senior unsecured sustainable bond issue
SEK 500M
March 2026
Glamox — Senior secured bond issue
€225M
March 2026
Pelagic Credit Plc. — Equity private placement and listing on Euronext Growth Oslo
$75M
March 2026
Ocean Yield AS — Senior unsecured bond issue
NOK 1.3B
March 2026
Otovo ASA — Private placement
$17M
February 2026
Panoro Energy — Senior secured bond tap issue
$150M
February 2026
SED Energy Holdings Plc — Secondary placing of existing shares
NOK 450M
February 2026
FinCo Opal S.à.r.l. — Senior secured bond issue
€150M
February 2026
Nordic Technology Group AS — Private placement
NOK 65M
February 2026
Bruton Ltd — Private placement
$50M
February 2026
Hospitality Invest — Senior unsecured bond tap issue
NOK 170M
Latest news
Arctic Asset Management - Arctic Asset Management - Markedskommentar mars 2026
Markedene i mars ble påvirket av krigen i Iran som har spredt seg til store deler av Midtøsten og skapt betydelige globale ringvirkninger. Etter at USA og Israel angrep Iran på den siste dagen i februar, har regionen vært preget av krigshandlinger, med påfølgende avbrudd i råvareproduksjon og forsyningskjeder som har gitt økt markedsvolatilitet.
Arctic Asset Management - No slowing down of Biotech M&A: Soleno to be acquired by Neurocrine
On April 6, Arctic Aurora LifeScience holdings Soleno Therapeutics and Neurocrine Biosciences announced an agreement in which the mid-cap commercial biotech Neurocrine acquires Soleno for USD 2.9 billion or USD 53 per share - a 34% premium over the last closing price.
Arctic Asset Management - Apellis to be acquired by Biogen for 140% premium
On March 31, Arctic Aurora LifeScience portfolio company Apellis Pharmaceuticals announced that the company had agreed to be acquired by Biogen for an upfront cash consideration of USD 5.6 billion, representing a 140% premium on the latest closing price.
Arctic Asset Management - Arctic Midt i Måneden - Global uro, energisjokk og markedsmuligheter
Geopolitisk uro, stigende energipriser og økt markedsvolatilitet preger finansmarkedene i mars. Hva betyr dette for renter, aksjer og investorers posisjonering fremover? I denne episoden av Arctic Midt i Måneden diskuterer Albert Collett sammen med Cathrine Foyn, Tone Varmann og Alexander Larstedt Lager hvordan krig og usikkerhet påvirker markedene – og hvor mulighetene kan ligge i en urolig tid.
Arctic Asset Management - Unlocking Alpha in Biotech Through Active Selection
Yesterday, two companies in the Arctic Aurora LifeScience portfolio reported positive clinical data, which was rewarded by the market. Clinical execution and identifying companies with differentiated drug candidates yields excess returns, as demonstrated by Xenon's share price, which appreciated by close to 50% on positive data, and Dianthus, which appreciated by 21%.